The Bayer pharmaceutical firm is a public partner of WHO. The new corporate mission statement underscores innovation and growth in the areas of health care, nutrition and high-tech materials. Bayer stresses its willingness to help shape the future and is determined to come up with innovations that benefit humankind. Bayer produces two drugs of major importance to HAT treatment, suramin for the treatment of sleeping sickness, and nifurtimox for Chagas disease (American Trypanosomiasis), which is also used off-label for HAT in combination with eflornithine. In 2002, Bayer agreed to donate suramin to WHO for the treatment of first stage rhodesiense sleeping sickness patients and in 2009 agreed to donate nifurtimox for its use in combination with eflornithine in the treatment of second stage of gambiense form. These donations have supposed a major contribution for the affected population living in the poorest rural areas of the african continent.